The Brockham Group was convened to investigate the growing problem of antibiotic resistance and to develop a strategy to improve our understanding and management of this phenomenon. Here they present their recommendations.
This is a preview of subscription content, log in via an institution to check access.
References
WHO Scientific Working Croup on Monitoring and Management of Bacterial Resistance to Antimicrobial Agents. WHO, Geneva WHO/CDS/BV I 7,1–33 (1995).
Cohen, M.L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257,1050–1055 (1992).
Tomasz, A. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University workshop. N. Engl. j. Med. 330,1247–1251 (1994).
Felmingham, D., Gruneberg, R.N. & The Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: j. Antimicrob. Chemother. 38, suppl A: 1–57 (1996).
Tomasz, A. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University workshop. N. Engl. j. Med. 330,1247–1251 (1994).
Klugman, K.P. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents for the treatment of community-acquired pneumonia. J. Antimicrob. Chemother. 38, suppl A: 133–140 (1996).
Seppala, H. et al. Finish study group for antimicrobial resistance. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N. Engl. j Med. 337,441 (1997).
Pallares, R. et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333,474–80 (1995).
Pinner, W.R. et al. Trends in infectious diseases mortality in the United States. IAMA 275,189–93(1996).
Sack, R.B., Rahman, M., Yunus, M. & Khan, E.H. Antimicrobial resistance in organisms causing diarrheal disease. Clin. Inf. Dis. 24, suppl 1: SI 02–5 (1997).
Bax, R.P. Antibiotic resistance: A view from the pharmaceutical industry. Clin. Inf. Dis. 24, suppl 1: SI51–3 (1997).
Chopra, I., Hodgson, J., Metcalf, B., Poste, G. New approaches to the control of infections caused by antibiotic-resistant bacteria. An Industry Perspective. IAMA 275, 401–3(1996).
Nystrom, P.O. et al. Proposed definitions for diagnosis, severity scoring, stratification and outcome for trials on intra abdominal infection. World. J. Sura 14,148–58 (1990).
Bax, R.P. Clinical trials and the pharmaceutical industry. J. Antimocrob. Chemother 21,278–80(1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bax, R., Anderson, R., Crew, J. et al. Antibiotic resistance - what can we do?. Nat Med 4, 545–546 (1998). https://doi.org/10.1038/nm0598-545
Issue Date:
DOI: https://doi.org/10.1038/nm0598-545
- Springer Nature America, Inc.
This article is cited by
-
Community knowledge and practices regarding antibiotic use in rural Mozambique: where is the starting point for prevention of antibiotic resistance?
BMC Public Health (2020)
-
Detecting and prioritizing biosynthetic gene clusters for bioactive compounds in bacteria and fungi
Applied Microbiology and Biotechnology (2019)
-
Characterization of the Bioactive Metabolites from a Plant Growth-Promoting Rhizobacteria and Their Exploitation as Antimicrobial and Plant Growth-Promoting Agents
Applied Biochemistry and Biotechnology (2015)
-
Non prescribed sale of antibiotics in Riyadh, Saudi Arabia: A Cross Sectional Study
BMC Public Health (2011)
-
Synthesis and antibacterial activity of novel 4″-carbamates of 6,11-di-O-methylerythromycin A
The Journal of Antibiotics (2010)